EUCAST Steering Committee Meeting Summary
Barcelona, Spain, 22-23 April 2008

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Prof Waleria Hryniewicz WH EUCAST Poland
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Inga Odenholt IO SRGA Sweden
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy CS CA-SFM France
Dr Martin Steinbakk MS NWGA Norway

Apologies
Prof Pietro Varaldo PV EUCAST Italy

EMEA (23 April)
Dr Eric Pelfrene MB EMEA, London
Dr Mair Powell MP MHRA, London
Dr Norbert Schnitzler NS Bonn, Germany

1 Chairman’s welcome

2 Minutes of meeting of 28-29 January 2008 Accepted as a correct record.

3 Matters arising from minutes of 28-29 January 2008
Minocycline MIC data is yet to be provided.
Quinupristin-dalfopristin data is to be requested.
Data relating to moxifloxacin for anaerobic intra-abdominal infections should be available soon.
Anaerobe MIC distributions are to be added to the wild type MIC distributions website.
Responses in relation to questions on a new glycopeptide have been received.
Proposals regarding revised breakpoints for a new carbapenem have been sent to the company.
A revised table on status of technical notes and rationale documents has been prepared.
Minutes related to meetings with companies on a new diaminopyrimidine and a new glycopeptide were sent to the companies.
Harmonised breakpoints for miscellaneous agent are close to completion.
Tetracycline breakpoints for N. gonorrhoeae were discussed.
Harmonised breakpoints for tetracyclines are close to completion.
A footnote regarding Shigella and azithromycin has been added to the macrolide breakpoint table.
Comments on proposed penicillin breakpoints were distributed with the latest version of the table.
Noted that proposed anaerobe breakpoints for penicillins were based on MIC distributions.
P. mirabilis has been added to footnote 5 of the cephalosporin breakpoint table.
4 **New drugs** The status of new agents was reviewed.

5 **EUCAST documents** The status of EUCAST documents was reviewed.

6 **Expert rules subcommittee** Version 1.0 of the document is on the EUCAST website. Possible future developments were discussed including publication as a supplement in CMI and development of a stand-alone program for application of the expert rules. If presenters agree, presentations from the ECCMID workshop will be posted in pdf format on the EUCAST website.

7 **Antifungal susceptibility testing subcommittee** Publication of a new document on susceptibility testing of filamentous fungi was discussed. A CEN/ISO method for antifungal agents is being developed.

8 **Anaerobe subcommittee** A proposal will be made to ECCMID to work on a microdilution method for anaerobes as agar dilution is currently recommended. Separate breakpoints have been proposed for Gram-positive and Gram-negative anaerobes.

9 **Penicillin breakpoints** The draft breakpoint table was reviewed and will be updated to what is expected to be the final version.

10 **Financing of EUCAST** ECDC will issue a new call for a susceptibility testing project. A separate call for development of a disk diffusion method is expected later this year.

11 **Review of EUCAST breakpoints** Breakpoint that require review were discussed and glycopeptides and staphylococci, ciprofloxacin and *Pseudomonas*, and carbapenems and *Enterobacteriaceae/Pseudomonas* were highlighted as priorities.

12 **CLSI** No new information.

13 **ECCMID** Noted that responses to the 2008 workshop and symposium were very positive and attendance was very good. Proposals for 2009 will be sent to ECCMID.

14 **Disk diffusion questionnaire** Replies had been received from almost all countries, with more than one reply from some. Almost all agree that a EUCAST disk diffusion method is needed and should be based on 0.5 MacFarland inoculum and MH agar.

15 **ECDC** National Antimicrobial Committees will be promoted for consultation, development of strategy and implementation of European decisions on all aspects of antimicrobials.

16 **New glycopeptide** Proposed breakpoints were discussed further.

17 **EMEA** The current status of new agents was presented.

18 **Oral cephalosporins** A draft table of breakpoints was reviewed.

19, 20 **New quinolone** The status was reviewed before a meeting with the company.

21 **Any other business** Prof Waleria Hryniewicz and Prof Pietro Varaldo have completed their terms as representatives of the EUCAST General Committee and were thanked for their contributions.

22 **Next meetings**
- 12-13 June 2008. Birmingham, UK
- 8-9 September 2008. Växjö, Sweden
- 24-25 November 2008. Rome, Italy
- 19-20 May 2009. Helsinki, Finland (following ECCMID)

Ratified summary of minutes of meeting 22-23 April 2008. Prepared by DB, GK and RC